In particular, Strategy 3 (an age-targeted strategy with a revised Bethesda criteria assessment before IHC and MS-MLPA for patients ≥ 70 years old) is the most cost-effective Strategy compared to Strategy 1 (sequencing of all MMR genes without prior tumor analysis) and Strategy 2 (sequential IHC and MS-MLPA analysis). This evidence concerns the gene MRC1 and neoplasm.